BM characteristics at follow-up time points
Parameter . | d 15 . | d 33 . | wk 12 . | wk 22-24 . |
---|---|---|---|---|
Total NC count3-150 | 4.3 (0.6-45) | 7.3 (0.9-32) | 15.7 (2-120) | 24.2 (2.4-75) |
Normal B cells3-151 | 14.6 (0.5-40) | 5.3 (0.3-40) | 1.2 (0.01-9) | 2.2 (0.04-19) |
BCP 13-152 | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 51.0 (0.0-99) | 44.5 (0.0-95) |
BCP 23-152 | 0.0 (0.0-5.0) | 0.0 (0.0-1.0) | 7.3 (0.0-57) | 25.7 (0.0-61) |
BCP 33-152 | 99.9 (95-100) | 98.2 (97.6-100) | 8.7 (0.0-82) | 6.8 (0.0-48) |
Plasma cells3-152 | 0.1 (0.0-0.9) | 1.2 (0.0-2.4) | 7.6 (0.0-77) | 4.7 (0.0-80) |
Threshold3-153 | 0.013 (0.001-0.32) | 0.01 (0.001-0.14) | 0.065 (0.002-2.7) | 0.07 (0.002-2.6) |
Parameter . | d 15 . | d 33 . | wk 12 . | wk 22-24 . |
---|---|---|---|---|
Total NC count3-150 | 4.3 (0.6-45) | 7.3 (0.9-32) | 15.7 (2-120) | 24.2 (2.4-75) |
Normal B cells3-151 | 14.6 (0.5-40) | 5.3 (0.3-40) | 1.2 (0.01-9) | 2.2 (0.04-19) |
BCP 13-152 | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 51.0 (0.0-99) | 44.5 (0.0-95) |
BCP 23-152 | 0.0 (0.0-5.0) | 0.0 (0.0-1.0) | 7.3 (0.0-57) | 25.7 (0.0-61) |
BCP 33-152 | 99.9 (95-100) | 98.2 (97.6-100) | 8.7 (0.0-82) | 6.8 (0.0-48) |
Plasma cells3-152 | 0.1 (0.0-0.9) | 1.2 (0.0-2.4) | 7.6 (0.0-77) | 4.7 (0.0-80) |
Threshold3-153 | 0.013 (0.001-0.32) | 0.01 (0.001-0.14) | 0.065 (0.002-2.7) | 0.07 (0.002-2.6) |
Total nucleated cells (including erythroid precursors) × 109/L; median (range); tested BM samples: day 15, n = 101; day 33, n = 103; week 12, n = 66; weeks 22-24, n = 54.
Percentage of CD19+ B cells among NCs; median (range); tested BM samples: day 15, n = 92; day 33, n = 93; week 12, n = 62; weeks 22-24, n = 47.
Proportion of BCP stage among total CD19+ B cells; median (range); tested BM samples: day 15, n = 87; day 33, n = 94; week 12, n = 34; weeks 22-24, n = 32.
Threshold proportions of NC at/above which samples were definitely MRD−, median (range); the threshold characterizes the test sensitivity in MRD− BM samples: day 15, n = 11; day 33, n = 62; week 12, n = 55; week 22-24, n = 48.